MedTrace Logo

A Study to Assess utiLity of BIoEP as an Early Prognostic Indicator for Predicting Anti-Seizure Medication (ASM) Efficacy

NCT06354868 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 158

Last updated 2024-08-13

No results posted yet for this study

Summary

This multisite prospective clinical study is to investigate the relationship between seizure type and frequency with the BioEP result during ASM titration in newly diagnosed patients with epilepsy, and to assess the utility of BioEP as an early prognostic indicator of ASM efficacy

Conditions

Sponsors & Collaborators

  • Cornwall Partnership NHS Foundation Trust

    collaborator NETWORK

  • Neuronostics Ltd

    lead INDUSTRY

Principal Investigators

  • Milaana Mainstone · Neuronostics Ltd

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-30
Primary Completion
2026-12-31
Completion
2027-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06354868 on ClinicalTrials.gov